



# Why Do We Treat Obesity?

Organ-Specific,  
Hormonal, and  
Biomechanical  
Complications



AACE OBESITY RESOURCE CENTER

AACE ONLINE ENDOCRINE ACADEMY



## 3.

## Treatment Based on Clinical Judgment

### TREATMENT GOALS BASED ON DIAGNOSIS IN THE MEDICAL MANAGEMENT OF PATIENTS WITH OBESITY

	DIAGNOSIS		TREATMENT GOALS	
	Anthropometric Component	Clinical Component	Intervention/ Weight-Loss Goal	Clinical Goals
TERTIARY PREVENTION				
Overweight or Obesity	BMI $\geq 25$ ( $\geq 23$ in certain ethnicities)	Polycystic ovary syndrome	5% to 15% or more	<ul style="list-style-type: none"> <li>• Ovulation</li> <li>• Regularization of menses</li> <li>• Reduced hirsutism</li> <li>• Enhanced insulin sensitivity</li> <li>• Reduced serum androgen levels</li> </ul>
		Female infertility	10% or more	<ul style="list-style-type: none"> <li>• Ovulation</li> <li>• Pregnancy and live birth</li> </ul>
		Male hypogonadism	5% to 10% or more	Increase in serum testosterone
		Obstructive sleep apnea	7% to 11% or more	<ul style="list-style-type: none"> <li>• Improved symptomatology</li> <li>• Decreased apnea-hypopnea index</li> </ul>
		Asthma/reactive airway disease	7% to 8% or more	<ul style="list-style-type: none"> <li>• Improvement in forced expiratory volume at 1 second</li> <li>• Improved symptomatology</li> </ul>
		Osteoarthritis	<ul style="list-style-type: none"> <li>• <math>\geq 10\%</math></li> <li>• 5% to 10% or more when coupled with exercise</li> </ul>	<ul style="list-style-type: none"> <li>• Improvement in symptomatology</li> <li>• Increased function</li> </ul>
		Urinary stress incontinence	5% to 10% or more	Reduced frequency of incontinence episodes
		Gastroesophageal reflux disease	10% or more	Reduced symptom frequency and severity
		Depression	Uncertain	<ul style="list-style-type: none"> <li>• Reduction in depression symptomatology</li> <li>• Improvement in depression scores</li> </ul>

Abbreviations: A1C = hemoglobin A1c; BMI = body mass index; BP = blood pressure; HDL-C = high-density lipoprotein cholesterol; T2DM = type 2 diabetes mellitus.



Organ-Specific, Hormonal, and Biomechanical  
Complications

# Gallbladder Disease

# The Paradox of Obesity and Gallbladder Disease

## Effect of Obesity

- Increased risk of cholesterol gallstones, cholecystitis, and gallbladder cancer, especially in women
  - Increased biliary fat may increase cholesterol in the gallbladder
- Risk increases with higher BMI

## Effect of Weight Loss

- Increased risk of gallstones
  - 10% to 25% of patients on diet-exercise regimens and up to 30% undergoing bariatric surgery develop gallstones
  - Higher risk in patients with a high BMI prior to weight loss or those who lose weight rapidly
- Oral ursodeoxycholic acid during weight loss may prevent gallstone formation

BMI = body mass index.

Everhart JE. *Ann Intern Med.* 1993;119:1029-1035. Erlinger S. *Eur J Gastroenterol Hepatol.* 2000;12:1347-1352.  
Pitt HA. *HPB (Oxford).* 2007;9:92-97.





Organ-Specific, Hormonal, and Biomechanical  
Complications

# Sex Hormone Disorders

# Polycystic Ovary Syndrome

## Disease Features

- Characterized by anovulation or irregular menstrual cycles with hyperandrogenism
  - Not a consequence of obesity, but may worsen with weight gain
  - Pathophysiologically linked to insulin resistance
- Increased risk for T2D, dyslipidemia, hypertension, inflammation, and CVD

## Treatment

- Increase insulin sensitivity
  - Aerobic exercise and weight loss
  - Metformin,\* pioglitazone,\*† or GLP-1 receptor agonist\*†
- Spironolactone or other nonandrogenic oral contraceptive for skin manifestations (hirsutism, acne)

\*Not FDA-approved for PCOS.

†Recommended only for women with IGT or T2D. Pregnancy category C—use with contraception in women of childbearing age.


CVD = cardiovascular disease; PCOS = polycystic ovary syndrome; T2D = type 2 diabetes.

Cobin RH, et al. *Endocr Pract.* 2005;11:126-134..


# Effect of Weight Loss on Female Infertility

Women With Obesity Presenting for Fertility Treatment  
(N=49)

## Weight Change After 12 Weeks



## Pregnancy Outcomes



\*Very-low-energy diet for first 6 weeks followed by a hypocaloric diet for next 6 weeks, with weekly multidisciplinary group meetings.

† Weight loss recommendations plus the same printed materials as intervention group.

Sim KA, et al. *Clin Obes*. 2014;4:61-68.

# Obesity and Testosterone Deficiency

## Disease Features

- Total testosterone <280-300 ng/dL and/or free testosterone <5-9 ng/dL\*
- Signs and symptoms: fatigue, decreased libido, ED, altered mood/cognition, decreased muscle mass and BMD, increased fat mass
- Strongly associated with metabolic syndrome
- Increased risk for T2D, dyslipidemia, hypertension, and CVD

## Treatment

- Weight loss
- Testosterone replacement therapy

\*Reference range varies with laboratory; use lower limit of normal.

BMD = bone mineral density; CVD = cardiovascular disease; ED = erectile dysfunction; T2D = type 2 diabetes.


Bhasin S, et al. *J Clin Endocrinol Metab.* 2010;95:2536-2559. Corona G, et al. *Eur J Endocrinol.* 2013;168:829-843.



# Androgen Deficiency and BMI

## Pooled Data From 2 Lipid Treatment Studies

(N=864 men)




\* $P < 0.05$  vs no metabolic syndrome.

BMI = body mass index.

Kaplan SA, et al. *J Urol*. 2006;176:1524-1527.

# Effects of Obesity, Metabolic Syndrome, and Age on Testosterone Levels



BMI = body mass index, in kg/m<sup>2</sup>; Met Syn = metabolic syndrome.


Kaplan SA, et al. *J Urol*. 2006;176:1524-1527.

# Effect of Weight Loss on Male Hypogonadism


## Observational Data

(N=33 men, mean WL = 18.8% [59.1 kg])

### Hypogonadism Before and 12 Months After Bariatric Surgery



### Change in Sex Hormones 12 Months After Bariatric Surgery



\* $P < 0.001$ , †  $P = 0.01$  vs value before surgery.

AMH = anti-Müllerian hormone; E2 = estradiol; FSH = follicle-stimulating hormone; FT = free testosterone; IB, inhibin B; LH = luteinizing hormone; PRL = prolactin; SHBG = sex hormone binding globulin; TT = total testosterone; WL = weight loss.

Pellitero S, et al. *Obes Surg.* 2012;22:1835-1842.




Organ-Specific, Hormonal, and Biomechanical  
Complications

# Pulmonary Disorders

# Obesity Adversely Affects Lung Function

- Stiffening of total respiratory system
  - Reduced lung and chest wall compliance
  - Reduced tidal volume and short, rapid breathing pattern
- Reduced lung volume and vital capacity
- Increased risk of airway closure and ventilation distribution abnormalities

## Flow-Volume Loops (Healthy, obese woman, age 35 years)



FRC = functional residual capacity; RV = reserve volume; TLC = total lung capacity; VC = vital capacity.

Salome CM, et al. *J Appl Physiol.* 2010;108:206-211.



# Obstructive Sleep Apnea

## Mechanisms

- Feedback loop involving interplay between excess visceral adipose tissue, insulin resistance, and inflammatory cytokines
  - Excess fat reduces diaphragm mobility and promotes soft tissue edema, which in turn lead to depression of ventilation
- Ventilation depression causes sleep apnea and poor sleep, which contributes to daytime sleepiness and fatigue
- Poor sleep promotes stress hormone and interleukin 6 production, which exacerbates insulin resistance

## Risk Factors


- Obesity
- Neck circumference >44 cm
- Narrowed airway
- Hypertension
- Smoking
- Male sex
- Age
- Family history
- Alcohol or sedatives

## Treatment Options

- Continuous positive airway pressure (CPAP)
- Adjustable airway pressure devices
- Oral appliances
- Surgery
  - Uvulopalatopharyngoplasty (UPPP)
  - Maxillomandibular advancement
  - Tracheostomy

# Effect of Weight Loss on OSA

## Sleep AHEAD Study (N=264 Patients With T2D)



DSE = diabetes support and education; ILI = intensive lifestyle intervention.

Foster GD, et al. *Arch Intern Med.* 2009;169:1619-1626.

# Effects of Weight Loss on Asthma and Reactive Airway Disease

- Calorie restriction with an average of 8% weight loss associated with improvements in asthma disease factors
  - Asthma symptoms
  - Quality of life
  - Peak expiratory flow
  - Markers of oxidative stress and inflammation
- After RYBG (WL ~23%), significant reductions in expression of:
  - Asthma-related genes
    - Interleukin-4
    - Disintegrin
    - Metalloproteinase 33
  - Tumor necrosis factor (ligand) superfamily member 14
  - Matrix metalloproteinase-9
  - C-C chemokine receptor type-2
  - Nitric acid metabolites

RYGB = Roux-en-Y gastric bypass; WL = weight loss.

Johnson JB, et al. *Free Radic Biol Med.* 2007;42(5):665-674. Dandona P, et al. *Obesity.* 2014;22(2):356-362.




Organ-Specific, Hormonal, and Biomechanical  
Complications

# Biomechanical Disorders

# Effect of Weight Loss on Osteoarthritis

## 18-Month Randomized, Controlled Weight Loss Study (N=399)




IL-6 = interleukin 6.

Messier SP, et al. *JAMA*. 2013;310:1263-1273.




# Effect of Weight Loss on Urinary Incontinence in Women

6-Month Randomized, Controlled Weight Loss Study  
(N=338)



# Effect of Weight Loss on Gastroesophageal Reflux Disease

6-Month Prospective Observational Weight Loss Study  
(N=332; mean WL:  $13 \pm 7.7$  kg)



GERD = gastroesophageal reflux disease.

Singh M, et al. *Obesity*. 2013;21:284-290.



Organ-Specific, Hormonal, and Biomechanical  
Complications

# Cancer

# Obesity and Cancer

## Increased Risks

- Obesity increases risk of the following cancers:
  - Colon
  - Endometrium
  - Postmenopausal breast
  - Kidney
  - Esophagus
  - Pancreas
  - Gallbladder
  - Liver
  - Hematological malignancies
- Obesity worsens prognosis and mortality risk

## Mechanism

- Obesity increases levels of leptin, IGF-1, and proinflammatory cytokines
  - These activate PI3K/Akt, which promotes cancer cell proliferation through mTOR
- Caloric restriction decreases levels of leptin, IGF-1, and proinflammatory cytokines
  - Signaling through AMPK is enhanced, promoting cancer cell apoptosis

AMPK = adenosine 5'-monophosphate-activated protein kinase; IGF-1 = insulin growth factor 1; mTOR = mammalian target of rapamycin; PI3K/Akt = phosphoinositide 3 kinase protein kinase B.

Vucenik I, Stains JP. *Ann NY Acad Sci.* 2012;1271:37-43.

# Summary

- Numerous organ-specific and mechanical complications accompany obesity
  - Gallbladder disease
  - Sex hormone–related disorders
    - Polycystic ovary disease
    - Female infertility and male hypogonadism
  - Pulmonary disorders
    - Obstructive sleep apnea
    - Asthma/reactive airway disease
  - Biomechanical disorders
    - Osteoarthritis
    - Urinary stress incontinence
    - Gastroesophageal reflux disease
- Weight loss ameliorates all of these conditions